Newspaper Publication for Audited Financials for the Q and Year ended 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sandu Pharmaceuticals has published its audited financial results for Q4 and full year ended March 31, 2026. Total income from operations for Q4 FY26 was Rs 1,721.85 lakhs, up from Rs 1,413.85 lakhs in Q4 FY25 but down from Rs 1,877.46 lakhs in Q3 FY26. The net profit after tax for Q4 FY26 was Rs 4.34 lakhs, significantly lower than Rs 32.64 lakhs in Q4 FY25 and Rs 97.51 lakhs in Q3 FY26. For the full year, total comprehensive income was Rs 242.95 lakhs compared to Rs 219.47 lakhs in the previous year. Reserves grew from Rs 2,379 lakhs to Rs 2,558.56 lakhs. The board meeting to approve these results was held on May 5, 2026, and results were published on May 7, 2026.
The sharp decline in Q4 net profit despite higher annual comprehensive income suggests weaker quarterly performance. Investors should note the low Q4 EPS of Rs 0.04 versus Rs 1.60 in Q4 FY25, indicating potential cost pressures or lower margins in the final quarter.